C57BL/6JCya-Gucy1a2em1flox/Cya
Common Name
Gucy1a2-flox
Product ID
S-CKO-17837
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-234889-Gucy1a2-B6J-VB
When using this mouse strain in a publication, please cite “Gucy1a2-flox Mouse (Catalog S-CKO-17837) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Gucy1a2-flox
Strain ID
CKOCMP-234889-Gucy1a2-B6J-VB
Gene Name
Product ID
S-CKO-17837
Gene Alias
6330407I18Rik, A230060L24Rik
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
Chr 9
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000115733
NCBI RefSeq
NM_001033322
Target Region
Exon 2~3
Size of Effective Region
~4.4 kb
Overview of Gene Research
Gucy1a2, encoding the soluble guanylyl cyclase (sGC) α2 subunit, is involved in the nitric oxide (NO)-cyclic guanosine phosphate (cGMP) signaling pathway, which plays crucial roles in blood pressure regulation, neurotransmitter delivery, renal function, and tumorigenesis [2].
In cerebral ischemia-reperfusion (I/R) injury, circ-Gucy1a2 was down-regulated in mouse brain tissues. Overexpression of circ-Gucy1a2 increased neuronal proliferation, mitigated apoptosis, mitochondrial membrane potential (MMP) loss, and oxidative stress in oxygen-glucose deprivation/reoxygenation (OGD/R) models, protecting mice from CI/RI [1].
In gastric cancer, GUCY1A2 was highly expressed, and its high expression was associated with histological grade, T stage, and poor prognosis. Gene set enrichment analysis (GSEA) showed it was enriched in tumor-associated signaling pathways [2].
A heterozygous gain-of-function variant in GUCY1A2 may cause autonomous ovarian hyperfunction, as in vitro activity assays revealed increased nitric oxide affinity for the mutant enzyme [3].
In infantile hemangiomas (IHs), GUCY1A2 was identified as one of the five diagnostic genes, and single-gene GSEA indicated it inhibited the "valine, leucine, and isoleucine degradation" pathway in IHs development [4].
In conclusion, Gucy1a2 is involved in multiple biological processes and diseases. The study of Gucy1a2, especially through model-based research such as in the CI/RI mouse model, helps to understand its functions in disease mechanisms, providing potential targets for treating cerebral ischemia-reperfusion injury, gastric cancer, ovarian hyperfunction, and IHs.
References：
1. Wang, Fei, Ma, Qian, Dong, Xinglu, Wang, Tinghuan, Ma, Chao. . circ-Gucy1a2 Protects Mice from Cerebral Ischemia-Reperfusion Injury by Attenuating Neuronal Apoptosis and Mitochondrial Membrane Potential Loss. In Journal of investigative surgery : the official journal of the Academy of Surgical Research, 36, 2152509. doi:10.1080/08941939.2022.2152509. https://pubmed.ncbi.nlm.nih.gov/37277119/
2. Li, Xin, Chen, Xiaowei, Hu, Xueju, Wu, Leilei, Shen, Xiaobing. 2021. Overexpression of GUCY1A2 Correlates With Poor Prognosis in Gastric Cancer Patients. In Frontiers in oncology, 11, 632172. doi:10.3389/fonc.2021.632172. https://pubmed.ncbi.nlm.nih.gov/34113559/
3. Wittrien, Theresa, Ziegler, Alban, Rühle, Anne, Coutant, Régis, Behrends, Sönke. . Heterozygous gain of function variant in GUCY1A2 may cause autonomous ovarian hyperfunction. In European journal of endocrinology, 190, 266-274. doi:10.1093/ejendo/lvae030. https://pubmed.ncbi.nlm.nih.gov/38578777/
4. Huang, Sicong, Chen, Ruiqi, Gao, Shihua, Shen, Gang, Jia, Hongyun. 2022. Identification of Diagnostic Markers in Infantile Hemangiomas. In Journal of oncology, 2022, 9395876. doi:10.1155/2022/9395876. https://pubmed.ncbi.nlm.nih.gov/36504560/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.